17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics

17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics

The continuum of oncology care extends far beyond initial antineoplastic order verification and regimen selection. Board-Certified Oncology Pharmacists (BCOPs) provide comprehensive, patient-centered clinical care spanning initial diagnosis education, therapeutic adherence monitoring, cancer survivorship transitions, and palliative end-of-life decision-making. Operating at the core of multidisciplinary cancer teams, clinical pharmacists empower patients through interactive education, mitigate devastating long-term and late treatment toxicities, and navigate complex biomedical ethical dilemmas surrounding goal concordance, symptom palliation, and resource allocation.

---

1. Patient & Caregiver Education in Clinical Oncology

Oral antineoplastics, targeted therapies, and complex parenteral regimens place substantial self-management responsibilities on patients and their family caregivers. Suboptimal adherence or improper administration of antineoplastic agents directly correlates with therapeutic failure, disease progression, or life-threatening toxicities.

+---------------------------------------------------------------------------------------------------+
|                         HOPA / ASCO PATIENT COUNSELING & EDUCATION STANDARDS                      |
|                                                                                                   |
|   [1. HEALTH LITERACY & COGNITIVE ASSESSMENT]                                                     |
|   - Screen for health literacy barriers using validated tools (e.g., Newest Vital Sign [NVS])     |
|   - Deliver all written educational materials at a **6th to 8th grade reading level**             |
|   - Utilize plain language (e.g., replace "myelosuppression" with "low blood counts and infection risk")|
|                                                                                                   |
|   [2. THE INTERACTIVE "TEACH-BACK" METHODOLOGY]                                                   |
|   - Do NOT ask closed-ended questions: "Do you understand how to take your pill?"                |
|   - DO ask open-ended demonstration questions:                                                    |
|     * "To ensure I explained this clearly, can you show me how you will take these tablets at home?"|
|     * "What will you do if you develop a fever of 100.5°F or notice severe diarrhea?"           |
|                                                                                                   |
|   [3. ESSENTIAL ORAL ONCOLYTIC COUNSELING DOMAINS]                                                |
|   - Precise dosing schedule, cycle length, and rest intervals (e.g., 21 days ON, 7 days OFF)      |
|   - Food / meal timing requirements (e.g., empty stomach vs with high-fat meals)                  |
|   - Missed dose protocol: **NEVER double up doses**; define drug-specific cutoff timeframes       |
|   - Management of emesis: Do NOT repeat dose if vomiting occurs after swallowing; resume next dose|
|   - Drug-drug & food interactions (e.g., CYP3A4 inhibitors/inducers, PPIs, grapefruit, St. John's)|
|                                                                                                   |
|   [4. SAFE HANDLING & DISPOSAL AT HOME]                                                           |
|   - Caregivers must wear disposable gloves when handling oral hazardous tablets/capsules          |
|   - Do NOT crush, cut, or open capsules/tablets unless explicitly approved by the pharmacist      |
|   - Store in original labeled container away from children, pets, excessive heat, and moisture    |
|   - Double-flush toilet with lid closed for 48–72 hours following chemotherapy administration     |
|   - Wash contaminated patient clothing/linens separately in hot water                             |
+---------------------------------------------------------------------------------------------------+

Oral Antineoplastic Food Requirements & Absorption Interactions

---

2. Cancer Survivorship Care & Long-Term Management

Advances in early cancer detection and targeted therapeutics have dramatically expanded the population of cancer survivors. However, survivors remain at high risk for chronic physical, psychological, and socioeconomic late effects of therapy.

The Institute of Medicine (IOM) Survivorship Framework

In its landmark report "From Cancer Patient to Cancer Survivor: Lost in Transition", the IOM established four essential components of survivorship care:

1. Prevention: Lifestyle interventions (smoking cessation, physical exercise, nutrition, UV protection) to prevent cancer recurrence and secondary primary neoplasms.
2. Surveillance: Systematic monitoring for cancer recurrence, metastatic spread, and secondary primary malignancies.
3. Intervention: Proactive management of chronic physical toxicities, organ dysfunction, pain, fatigue, and psychological distress.
4. Coordination: Structured communication between oncology specialists and primary care clinicians through a formal Survivorship Care Plan (SCP).

+---------------------------------------------------------------------------------------------------+
|                         SURVIVORSHIP CARE PLAN (SCP) CORE COMPONENTS                              |
|                                                                                                   |
|   [TREATMENT SUMMARY]                                                                             |
|   - Exact histologic diagnosis, initial staging, and molecular biomarkers                         |
|   - Complete surgical procedures and anatomical radiation therapy fields with cumulative Gray (Gy)|
|   - Detailed chemotherapy/immunotherapy regimen names, cycle counts, and **cumulative doses**:   |
|     * Total cumulative Anthracycline dose (mg/m2 doxorubicin equivalents)                         |
|     * Total cumulative Bleomycin dose (Units)                                                     |
|   - Grade 3/4 acute toxicities, hypersensitivity reactions, or dose reductions during therapy      |
|                                   |                                                               |
|                                   v                                                               |
|   [FOLLOW-UP SURVEILLANCE & CARE PLAN]                                                            |
|   - Schedule of surveillance imaging, laboratory tests, and clinical examinations                 |
|   - Long-term late effect screening (ECHO/MUGA, PFTs, DXA scans, lipid panels, TSH)               |
|   - Routine cancer screening guidelines for secondary primary cancers (Mammography, Colonoscopy)  |
|   - Recommended supportive medications, vaccinations, and healthy lifestyle guidelines            |
+---------------------------------------------------------------------------------------------------+

High-Yield Chronic & Late Physical Toxicities

+---------------------------------------------------------------------------------------------------+
|                         SPECTRUM OF CHRONIC & LATE ONCOLOGY TOXICITIES                            |
|                                                                                                   |
|   [1. SECONDARY MALIGNANCIES]                                                                     |
|   - **Therapy-Related Myelodysplastic Syndrome / AML (t-MDS/AML):**                               |
|     * Alkylating agents (Cyclophosphamide, Melphalan): 5–10 year latency, -5/del(5q), -7/del(7q)  |
|     * Topoisomerase II inhibitors (Etoposide, Doxorubicin): 1–3 year latency, 11q23 (MLL) transloc|
|   - **Radiation-Induced Solid Tumors:** 10–20+ year latency within radiation fields               |
|                                                                                                   |
|   [2. DELAYED CARDIOTOXICITY & VASCULOPATHY]                                                      |
|   - **Type I Anthracycline Cardiomyopathy:** Irreversible myocyte loss/fibrosis; monitor serial   |
|     ECHO/LVEF; manage with ACE inhibitors/ARBs and beta-blockers (carvedilol).                    |
|   - **Mediastinal Radiation:** Accelerated coronary artery disease, valvular stenosis, pericarditis|
|   - **VEGF TKIs & BCR-ABL Inhibitors (Ponatinib, Nilotinib):** Severe arterial occlusive events,  |
|     myocardial infarction, stroke, peripheral artery disease.                                     |
|                                                                                                   |
|   [3. CANCER-RELATED BONE LOSS & OSTEOPOROSIS]                                                    |
|   - Aromatase Inhibitors (Anastrozole, Letrozole) & Androgen Deprivation Therapy (GnRH agonists): |
|     Severe estrogen/androgen depletion accelerating bone resorption and fracture risk.             |
|   - Management: Baseline DXA scan; Calcium 1000–1200 mg/day + Vitamin D3 800–1000 IU/day;        |
|     Antiresorptive therapy: **Zoledronic acid 4 mg IV q6 months** or **Denosumab 60 mg SC q6m**.    |
|                                                                                                   |
|   [4. CHRONIC CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)]                                  |
|   - Causative Agents: Oxaliplatin (cold-induced & chronic sensory), Paclitaxel, Vincristine,      |
|     Bortezomib, Thalidomide.                                                                      |
|   - First-Line Evidence-Based Treatment (ASCO Guidelines): **Duloxetine 30–60 mg PO once daily** |
|     (Only agent with proven Phase III randomized trial efficacy for established painful CIPN).    |
|                                                                                                   |
|   [5. INFERTILITY & GONADAL DYSFUNCTION]                                                          |
|   - High-dose alkylators (Cyclophosphamide, Busulfan) cause dose-dependent permanent azoospermia   |
|     and premature ovarian failure.                                                                |
|   - Mandatory upfront counseling: Sperm banking for males; oocyte/embryo cryopreservation or      |
|     GnRH agonist ovarian suppression (goserelin) for premenopausal females prior to chemotherapy. |
+---------------------------------------------------------------------------------------------------+

---

3. Palliative Care, Advance Care Planning & Biomedical Ethics

Early Concurrent Palliative Care Integration

Palliative care is specialized medical care for patients living with a serious illness, focused on providing relief from symptoms, pain, and physical/psychosocial distress—regardless of cancer stage or prognosis.

Landmark Evidence (Temel et al., NEJM 2010): In a seminal randomized controlled trial in metastatic non-small cell lung cancer, patients receiving early concurrent palliative care integrated at diagnosis alongside standard oncology care experienced significantly improved Quality of Life (QoL), lower rates of depression, fewer aggressive interventions at end-of-life, and a clinically significant 2.7-month prolongation of overall survival compared to standard oncology care alone.

Palliative Care vs. Hospice Care

• Palliative Care: Available at any stage of a serious illness; provided concurrently with curative or life-prolonging antineoplastic treatments; no life expectancy restriction.
• Hospice Care: A specific form of palliative care delivered when curative therapies have ceased and clinical prognosis is certified by physicians to be 6 months or less if the disease follows its natural course.

Advance Care Planning: Documents vs Actionable Medical Orders

+---------------------------------------------------------------------------------------------------+
|                         ADVANCE DIRECTIVES vs. POLST / MOLST ORDERS                               |
|                                                                                                   |
|   [ADVANCE DIRECTIVE / LIVING WILL]                                                               |
|   - Legal document completed by a competent patient detailing future healthcare preferences.       |
|   - Appoints a Durable Power of Attorney for Healthcare (Healthcare Proxy / Surrogate).           |
|   - **Limitation:** General statements of preference; NOT an actionable medical order for EMS/ED!  |
|                                                                                                   |
|   [POLST / MOLST (Provider/Medical Orders for Life-Sustaining Treatment)]                         |
|   - **Actionable, standardized medical order form** signed by a licensed clinician (MD/DO/NP/PA). |
|   - Translates patient preferences into immediate medical orders across all healthcare settings:  |
|     * Section A: Cardiopulmonary Resuscitation (CPR vs DNR / Allow Natural Death)                |
|     * Section B: Medical Interventions (Full Treatment vs Selective Treatment vs Comfort-Focused) |
|     * Section C: Artificially Administered Nutrition (Long-term feeding tube vs Trial vs None)    |
|   - **Key Advantage:** Immediately enforceable by Emergency Medical Services (EMS) in the field! |
+---------------------------------------------------------------------------------------------------+

---

4. The Four Foundational Principles of Biomedical Ethics

In oncology clinical practice, pharmacists regularly encounter complex ethical dilemmas that must be analyzed through the four classical principles of biomedical ethics (Beauchamp and Childress):

+---------------------------------------------------------------------------------------------------+
|                         THE FOUR PRINCIPLES OF BIOMEDICAL ETHICS IN ONCOLOGY                      |
|                                                                                                   |
|   [1. AUTONOMY]                                                                                   |
|   - Respecting the moral right of competent individuals to make self-directed medical decisions.  |
|   - Requires comprehensive informed consent, truth-telling regarding prognosis, and respecting    |
|     the patient's right to decline or withdraw life-prolonging antineoplastics.                   |
|                                                                                                   |
|   [2. BENEFICENCE]                                                                                |
|   - The active duty to act in the best interest of the patient; promoting well-being and health.  |
|   - Optimizing symptom relief, providing evidence-based supportive care, and palliating suffering.|
|                                                                                                   |
|   [3. NON-MALEFICENCE]                                                                            |
|   - The fundamental obligation to "Do No Harm" (primum non nocere).                              |
|   - Intercepting medication errors; preventing administration of toxic, futile chemotherapy to    |
|     severely deteriorating patients (ECOG PS 4) where toxicity vastly outweighs any benefit.       |
|                                                                                                   |
|   [4. JUSTICE]                                                                                    |
|   - Fair, equitable, and non-discriminatory distribution of healthcare resources and burdens.     |
|   - Ethical drug shortage allocation frameworks, eliminating racial/socioeconomic disparities.    |
+---------------------------------------------------------------------------------------------------+

Specific End-of-Life Ethical Dilemmas

1. Withholding vs. Withdrawing Life-Sustaining Treatment

In clinical ethics and United States law, withholding (not initiating) and withdrawing (discontinuing) life-sustaining treatments (e.g., mechanical ventilation, hemodialysis, total parenteral nutrition, or intravenous antineoplastics) are morally, ethically, and legally equivalent. If a treatment no longer benefits the patient or conflicts with their documented goals of care, withdrawing that intervention is fully ethical and does not constitute euthanasia or physician-assisted suicide.

2. The Principle of Double Effect

The Principle of Double Effect (PDE) provides ethical justification for administering escalating doses of opioids or sedatives to manage refractory pain or severe dyspnea in terminally ill cancer patients, even if the medication carries the foreseeable secondary risk of hastening death (e.g., through respiratory depression), provided four criteria are met:

1. The act itself (administering analgesia for symptom relief) must be morally good or neutral.
2. The clinician’s direct intention must be solely to relieve severe suffering, not to cause death.
3. The bad effect (death) must not be the means used to achieve the good effect (pain relief).
4. The therapeutic benefit (profound symptom relief) must be proportionally critical to justify the foreseen risk.

3. Palliative Sedation for Refractory Suffering

Palliative sedation involves the monitored administration of non-opioid sedatives (e.g., continuous IV midazolam infusion) to reduce consciousness in terminally ill patients with refractory, unbearable physical symptoms (e.g., intractable dyspnea, massive terminal hemorrhage, severe agitated delirium) that cannot be controlled by all other aggressive palliative measures. It is strictly titrated to the minimum depth of sedation required to relieve distress.

4. Ethical Frameworks for Managing Oncology Drug Shortages

When life-saving antineoplastics (e.g., carboplatin, cisplatin, methotrexate) face severe national shortages, institutions must implement transparent, ethically grounded allocation frameworks overseen by multidisciplinary triage teams (removing bedside clinicians from direct rationing decisions):

• Curative Intent Priority: Prioritizing scarce agents for patients treated with curative, adjuvant, or neoadjuvant intent over purely palliative non-curative maintenance therapy where evidence-based alternative regimens exist.
• Therapeutic Equivalence Substitution: Utilizing evidence-based alternative platinum or antimetabolite agents supported by P&T clinical practice guidelines.
• Lottery / Random Allocation: Utilizing randomized allocation among clinically identical patient tiers rather than "first-come, first-served" models that exacerbate racial and socioeconomic inequities.